Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1481-1500 of 2,120 trials

Ovarian Cancer: Rinatabart Sesutecan (Rina-S) Study

We are comparing a new treatment, Rina-S, to standard therapies for patients with platinum-resistant ovarian cancer. The goal is to see if Rina-S can help improve survival without disease progression.

Platinum-resistant Ovarian Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Chronic Lymphocytic Leukemia: Ibrutinib and Obinutuzumab Treatment

We are studying a combination of ibrutinib and obinutuzumab for newly diagnosed patients with Chronic Lymphocytic Leukemia. The aim is to see if this treatment effectively reduces cancer cells in the bone marrow.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Solid Tumors: OSE-279 Treatment Study

We are investigating a new monoclonal antibody, OSE-279, for patients with advanced solid tumors or lymphomas. The study aims to find the best dose and evaluate its safety and effectiveness compared to existing treatments.

Stage IV Non-Small Cell Lung CancerAdvanced Solid TumorsLymphoma1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Rectal Cancer: Ferumoxtran-10 MRI Study

We are testing a new MRI method to see if it better identifies lymph node involvement in patients with newly diagnosed rectal cancer. This may help doctors plan more effective treatments.

Rectal CancerMesorectal Lymph Node Metastases>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

Severe Asthma: Predicting Response to Benralizumab

We are studying whether early blood tests can predict how well severe asthma patients respond to Benralizumab treatment. This may help identify those who are likely to experience fewer asthma attacks.

Severe Asthma>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

Unilateral Retinoblastoma: Adjuvant Treatment Study

We are studying additional treatments for patients with unilateral retinoblastoma after eye removal. The goal is to understand how these treatments affect recovery and any potential side effects.

Retinoblastoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOphthalmology

Scoliosis Surgery: Pooled Plasma vs. Crystalloid

We are studying whether pooled human plasma can reduce blood loss during spinal fusion surgery in children with scoliosis compared to a standard fluid. This trial aims to improve fluid management during surgery.

Neuromuscular ScoliosisAdolescent Idiopathic Scoliosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOrthopedics and TraumatologyPediatrics

Dilated Cardiomyopathy: Anakinra Treatment Study

We are investigating whether the medication Anakinra can improve heart function in people with dilated cardiomyopathy. This study compares Anakinra plus standard care to standard care alone.

Inflammatory Dilated Cardiomyopathy>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Glioblastoma: Bevacizumab with Radiochemotherapy

We are studying a new treatment approach for patients with newly diagnosed glioblastoma to see if it improves survival and quality of life. The trial also evaluates safety and cognitive effects.

Glioblastoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Soft-Tissue Sarcomas: Next-Generation Sequencing Study

We are exploring whether high-throughput molecular analysis can help guide treatment for patients with advanced soft-tissue sarcomas. This study will compare treatment outcomes for those receiving NGS-guided therapy versus standard care.

Unresectable Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Head and Neck Cancer: Shortened Chemotherapy with Pembrolizumab

We are studying a shorter chemotherapy treatment combined with Pembrolizumab for patients with PD-L1-positive recurrent or metastatic head and neck cancer. The goal is to see if this approach is effective and safe compared to standard treatments.

Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

MDS and AML: Venetoclax with Azacitidine

We are studying a new treatment combining venetoclax and azacitidine with donor lymphocyte infusion for patients with MDS or AML who have relapsed after a stem cell transplant. The goal is to assess its safety and effectiveness.

Acute Myeloid LeukemiaMyelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Gastric Cancer: IP Paclitaxel and Systemic Therapy Study

We are comparing the effects of intraperitoneal paclitaxel combined with standard therapy against standard therapy alone in patients with gastric cancer and peritoneal metastases. This study aims to see if the combination improves survival and quality of life.

Metastatic Gastric Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Pemphigus: Personalized Treatment Strategy vs. Standard Care

We are studying whether a personalized treatment plan based on specific blood markers can reduce relapse rates in pemphigus patients compared to standard treatment with rituximab and corticosteroids.

Pemphigus Diseases>2 yearsMonitoring phase (IV)>20 visitsNo PlaceboStandard MedicinesDermatologyRheumatology

Acute Hyperkalemia: Comparing Treatments

We are studying whether insulin/dextrose infusion, nebulized salbutamol, or their combination is more effective in lowering high potassium levels in emergency patients. This research aims to find the best first-line treatment for acute hyperkalemia.

High Potassium Levels>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Short Course Antibiotics for Gram-Negative Bacteremia

We are studying whether a 5-day antibiotic treatment is as effective and safe as longer treatments for hospitalized adults with Gram-negative bacteremia from urinary tract infections.

Gram-negative Bacteremia3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Type 1 Diabetes: Semaglutide Treatment Study

We are investigating whether adding semaglutide to standard treatment helps people with type 1 diabetes and 'double diabetes' better control their blood sugar and weight. This study will also look at insulin use and potential side effects.

Double Diabetes6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology

Hepatocellular Carcinoma: Durvalumab and Tremelimumab Study

We are comparing two treatment methods for patients with liver cancer to see if combining immune therapy with chemotherapy improves outcomes. The study will assess effectiveness, safety, and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Emergency Tracheal Intubation: New Optimization Strategy

We are studying a new method for emergency tracheal intubation to see if it reduces complications in adult patients. This approach combines medication and ventilation techniques to improve patient safety during emergencies.

Respiratory Distress>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard Medicines

Sepsis-Induced Hypotension: REGN7544 Treatment Study

We are studying REGN7544 to see if it can help adults with sepsis-induced hypotension manage their blood pressure and reduce the need for other medications. The trial will also assess the safety and effects of this treatment.

Sepsis-Induced Hypotension3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInfectious Diseases